MX371128B - Compuestos de dihidropirimidin-2-ona y su uso medico. - Google Patents

Compuestos de dihidropirimidin-2-ona y su uso medico.

Info

Publication number
MX371128B
MX371128B MX2017007577A MX2017007577A MX371128B MX 371128 B MX371128 B MX 371128B MX 2017007577 A MX2017007577 A MX 2017007577A MX 2017007577 A MX2017007577 A MX 2017007577A MX 371128 B MX371128 B MX 371128B
Authority
MX
Mexico
Prior art keywords
compounds
dihydropyrimidine
medicinal uses
formula
medicinal
Prior art date
Application number
MX2017007577A
Other languages
English (en)
Other versions
MX2017007577A (es
Inventor
Taku Ikenogami
Masahiro Yokota
Makoto Shiozaki
Yosuke Ogoshi
Katsuya Maeda
Noriyoshi Seki
Takayuki Sakai
Watanabe Eiichi
Fujioka Shingo
Suwa Katsunori
Noguchi Masato
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of MX2017007577A publication Critical patent/MX2017007577A/es
Publication of MX371128B publication Critical patent/MX371128B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C265/00—Derivatives of isocyanic acid
    • C07C265/02—Derivatives of isocyanic acid having isocyanate groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/12—Organo silicon halides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

Un compuesto de Fórmula [I] o una de sus sales farmacéuticamente aceptables: (ver Fórmula) donde cada símbolo se define como en la memoria descriptiva.
MX2017007577A 2014-12-12 2015-12-11 Compuestos de dihidropirimidin-2-ona y su uso medico. MX371128B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014251771 2014-12-12
PCT/JP2015/084791 WO2016093342A1 (ja) 2014-12-12 2015-12-11 ジヒドロピリミジン－２－オン化合物およびその医薬用途

Publications (2)

Publication Number Publication Date
MX2017007577A MX2017007577A (es) 2017-09-28
MX371128B true MX371128B (es) 2020-01-17

Family

ID=56107519

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017007577A MX371128B (es) 2014-12-12 2015-12-11 Compuestos de dihidropirimidin-2-ona y su uso medico.

Country Status (34)

Country Link
US (4) US10196363B2 (es)
EP (2) EP3744713A1 (es)
JP (4) JP6757565B2 (es)
KR (1) KR102551018B1 (es)
CN (1) CN107001286B (es)
AR (1) AR102972A1 (es)
AU (1) AU2015362394C1 (es)
BR (1) BR112017010471B1 (es)
CA (1) CA2965804C (es)
CL (1) CL2017001467A1 (es)
CO (1) CO2017005732A2 (es)
CY (1) CY1122971T1 (es)
DK (1) DK3231793T3 (es)
ES (1) ES2787700T3 (es)
HR (1) HRP20200584T1 (es)
HU (1) HUE048503T2 (es)
IL (2) IL251940B (es)
LT (1) LT3231793T (es)
ME (1) ME03760B (es)
MX (1) MX371128B (es)
MY (1) MY193671A (es)
PE (1) PE20171119A1 (es)
PH (1) PH12017501071B1 (es)
PL (1) PL3231793T3 (es)
PT (1) PT3231793T (es)
RS (1) RS60352B1 (es)
RU (1) RU2770061C2 (es)
SA (1) SA517381678B1 (es)
SG (2) SG10202010291VA (es)
SI (1) SI3231793T1 (es)
SM (1) SMT202000215T1 (es)
TW (2) TWI739206B (es)
WO (1) WO2016093342A1 (es)
ZA (1) ZA201703976B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202010291VA (en) * 2014-12-12 2020-11-27 Japan Tobacco Inc Dihydropyrimidin-2-one compounds and medical use thereof
CN106496008A (zh) * 2016-10-20 2017-03-15 上海毕得医药科技有限公司 一种合成4‑(4‑氯苯基)环己酮的方法
SG11202007117RA (en) 2018-02-28 2020-08-28 Japan Tobacco Inc 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof
WO2019167982A1 (ja) * 2018-02-28 2019-09-06 日本たばこ産業株式会社 飽和環縮合ジヒドロピリミジノン又はジヒドロトリアジノン化合物及びその医薬用途
CN110294762B (zh) * 2019-06-14 2020-12-15 深圳市疾病预防控制中心（深圳市卫生检验中心、深圳市预防医学研究所） 检测米酵菌酸中毒的人工抗原及应用
WO2021149786A1 (en) 2020-01-24 2021-07-29 Japan Tobacco Inc. Methods of treating cancer using dihydropyrimidin-2-one compounds
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485107A (en) * 1982-11-01 1984-11-27 Janssen Pharmaceutica N.V. [[Bis(aryl)methylene]-1-piperidinyl]alkyl-pyrimidinones
TW201900217A (zh) * 2005-12-22 2019-01-01 美商海卓勒生物科學公司 用於調節ｔｒｐａ１功能之化合物
DE102006031314A1 (de) * 2006-07-01 2008-01-03 Bayer Healthcare Aktiengesellschaft Verwendung von 1,4-Diaryl-dihydropyrimidin-2-on-Derivaten zur Behandlung der pulmonalen arteriellen Hyptertonie
WO2009019174A1 (en) 2007-08-09 2009-02-12 F. Hoffmann-La Roche Ag Benzoyl-piperidine derivatives as dual modulators of the 5-ht2a and d3 receptors
WO2009150668A1 (en) * 2008-06-13 2009-12-17 Delhi University Dihydropyridimidinone compounds for the treatment of cardiovascular diseases and process for preparing the same
CA2833493C (en) 2011-04-28 2020-06-02 Japan Tobacco Inc. Amide compound and pharmaceutical application therefor
EP2682389A1 (en) 2012-07-02 2014-01-08 Commissariat A L'energie Atomique Et Aux Energies Alternatives Dihydropyrimidin-2(1H)-ones and dihydropyrimidin-2(1H)-thiones as inhibitors of sodium iodide symporter
US10035790B2 (en) 2012-10-19 2018-07-31 Exelixis, Inc. RORγ modulators
WO2014065413A1 (ja) * 2012-10-26 2014-05-01 日本たばこ産業株式会社 トリアゾール・イソオキサゾール化合物およびその医薬用途
CN103113308B (zh) * 2013-01-25 2014-11-19 浙江大学 一种制备二氢嘧啶酮衍生物的方法
MA41148A (fr) 2014-12-12 2017-10-17 H Lundbeck As Procédé de fabrication d'idalopirdine
CN106999493A (zh) 2014-12-12 2017-08-01 默克专利股份公司 具有抗癌活性的6‑氧代‑1,6‑二氢‑哒嗪衍生物与egfr抑制剂的组合
US20160168089A1 (en) 2014-12-12 2016-06-16 H. Lundbeck A/S Process for the manufacture of idalopirdine
HK1251566A1 (zh) 2014-12-12 2019-02-01 Regenacy Pharmaceuticals, Llc 作为hdac1/2抑制剂的呱啶衍生物
SG10202010291VA (en) * 2014-12-12 2020-11-27 Japan Tobacco Inc Dihydropyrimidin-2-one compounds and medical use thereof

Also Published As

Publication number Publication date
RU2017124423A (ru) 2019-01-15
LT3231793T (lt) 2020-04-27
RU2017124423A3 (es) 2019-08-13
IL283335B (en) 2022-04-01
AR102972A1 (es) 2017-04-05
BR112017010471B1 (pt) 2024-02-27
PE20171119A1 (es) 2017-08-08
EP3744713A1 (en) 2020-12-02
JP2020200339A (ja) 2020-12-17
US20190359575A1 (en) 2019-11-28
SA517381678B1 (ar) 2021-12-14
CA2965804C (en) 2023-10-10
SI3231793T1 (sl) 2020-07-31
CO2017005732A2 (es) 2017-08-31
TWI690515B (zh) 2020-04-11
MY193671A (en) 2022-10-24
IL283335A (en) 2021-07-29
PH12017501071B1 (en) 2023-08-30
US10196363B2 (en) 2019-02-05
AU2015362394C1 (en) 2021-01-28
HRP20200584T1 (hr) 2020-07-10
KR20170090497A (ko) 2017-08-07
JP2022116239A (ja) 2022-08-09
TWI739206B (zh) 2021-09-11
SMT202000215T1 (it) 2020-05-08
EP3231793B1 (en) 2020-03-11
ME03760B (me) 2021-04-20
AU2015362394A1 (en) 2017-05-25
PT3231793T (pt) 2020-05-06
TW201639820A (zh) 2016-11-16
JP6757565B2 (ja) 2020-09-23
IL251940A0 (en) 2017-06-29
US20210130300A1 (en) 2021-05-06
TW202012377A (zh) 2020-04-01
MX2017007577A (es) 2017-09-28
PL3231793T3 (pl) 2020-07-27
CA2965804A1 (en) 2016-06-16
CN107001286A (zh) 2017-08-01
CY1122971T1 (el) 2021-10-29
NZ731607A (en) 2024-03-22
US20230373932A1 (en) 2023-11-23
JP2016113455A (ja) 2016-06-23
SG11201703885TA (en) 2017-06-29
ZA201703976B (en) 2019-06-26
JP2024133646A (ja) 2024-10-02
ES2787700T3 (es) 2020-10-16
IL251940B (en) 2021-06-30
KR102551018B1 (ko) 2023-07-05
PH12017501071A1 (en) 2017-12-18
HUE048503T2 (hu) 2020-07-28
EP3231793A1 (en) 2017-10-18
DK3231793T3 (da) 2020-05-11
RU2770061C2 (ru) 2022-04-14
CN107001286B (zh) 2020-07-07
BR112017010471A2 (pt) 2017-12-26
CL2017001467A1 (es) 2018-01-05
RS60352B1 (sr) 2020-07-31
SG10202010291VA (en) 2020-11-27
WO2016093342A1 (ja) 2016-06-16
AU2015362394B2 (en) 2020-07-02
US20160194290A1 (en) 2016-07-07
EP3231793A4 (en) 2018-09-19

Similar Documents

Publication Publication Date Title
PH12015502401A1 (en) Compositions and methods for enhancing microbial stability
PH12014502398B1 (en) Pesticidal compositions and processes related thereto
MX2016006432A (es) Tetrahidro-benzodiazepinonas.
PH12015501393A1 (en) Pesticidal compositions and processes related thereto
EP3139769A4 (en) Nutrient rich compositions
MX2017007577A (es) Compuestos de dihidropirimidin-2-ona y su uso medico.
PH12015501588B1 (en) Compounds and methods for treating bacterial infections
AU2015352440B2 (en) Compounds
PH12015502665A1 (en) Improvements in or relating to organic compounds
MX2015011837A (es) Co-cristale de pirimetanil y tetracarboximida de ditiina seleccionada.
PH12016501252A1 (en) Novel tetrahydropyridopyrimidine compound or salt thereof
PH12016501865A1 (en) Pyridine-2-amides useful as cb2 agonists
MX2015008829A (es) Momelotinib deuterado.
NZ731344A (en) Hydroxyl purine compounds and applications thereof
IN2014MU00455A (es)
IL248783A0 (en) Fluorescence quenching compounds, preparations containing them and their uses
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
IN2013MU03216A (es)
MX2015012610A (es) Pacritinib deuterizado.
EP3206683A4 (en) Novel methods, compounds, and compositions for anesthesia
UA91886U (uk) 1-трет-бутокси-3-(2,2,6,6-тетраметил-4-гідроксипіперидино)-2-пропанол
TN2014000522A1 (fr) لوح مدرسي بوجهين
UA99992U (ru) 2-оксо-4-фенил-5-циано-1,2,3,4-тетрагидропиридин-6-тиолат n-метилморфолиния
UA94338U (uk) 2-ОКСО-5-ФЕНІЛ-2,3-ДИГІДРО-ТІАЗОЛО[4,5-b]ПІРИДИН-7-КАРБОНОВА КИСЛОТА, ЩО ПРОЯВЛЯЄ АНТИЕКСУДАТИВНУ ДІЮ
UA80877U (en) 2-hydroxyethyl-1,3,4-trimethylcyclohex-3-ene-1-carboxylate

Legal Events

Date Code Title Description
FG Grant or registration